A new trading day began on Monday, with Elevation Oncology Inc (NASDAQ: ELEV) stock price down -8.57% from the previous day of trading, before settling in for the closing price of $0.52. ELEV’s price has ranged from $0.50 to $5.83 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 36.80%. With a float of $51.98 million, this company’s outstanding shares have now reached $59.12 million.
The extent of productivity of a business whose workforce counts for 29 workers is very important to gauge. In terms of profitability, gross margin is 50.0%, operating margin of -72425.86%, and the pretax margin is -72250.0%.
Elevation Oncology Inc (ELEV) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Elevation Oncology Inc is 12.07%, while institutional ownership is 56.11%.
Elevation Oncology Inc (ELEV) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 36.80% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.33% during the next five years compared to -52.56% drop over the previous five years of trading.
Elevation Oncology Inc (NASDAQ: ELEV) Trading Performance Indicators
Here are Elevation Oncology Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 17.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.81, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.89 in one year’s time.
Technical Analysis of Elevation Oncology Inc (ELEV)
The latest stats from [Elevation Oncology Inc, ELEV] show that its last 5-days average volume of 1.25 million was inferior to 2.88 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 5.42%. Additionally, its Average True Range was 0.06.
During the past 100 days, Elevation Oncology Inc’s (ELEV) raw stochastic average was set at 1.96%, which indicates a significant decrease from 4.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.99% in the past 14 days, which was lower than the 94.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6403, while its 200-day Moving Average is $1.3336. Now, the first resistance to watch is $0.5300. This is followed by the second major resistance level at $0.5800. The third major resistance level sits at $0.6100. If the price goes on to break the first support level at $0.4500, it is likely to go to the next support level at $0.4200. Assuming the price breaks the second support level, the third support level stands at $0.3700.
Elevation Oncology Inc (NASDAQ: ELEV) Key Stats
With a market capitalization of 28.32 million, the company has a total of 59,119K Shares Outstanding. Currently, annual sales are 0 K while annual income is -45,700 K. The company’s previous quarter sales were 0 K while its latest quarter income was -12,880 K.
